Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Debt (2016 - 2025)

IGC Pharma has reported Total Debt over the past 16 years, most recently at $132000.0 for Q3 2025.

  • Quarterly Total Debt fell 2.22% to $132000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $132000.0 through Sep 2025, down 2.22% year-over-year, with the annual reading at $134000.0 for FY2025, 2.19% down from the prior year.
  • Total Debt was $132000.0 for Q3 2025 at IGC Pharma, down from $133000.0 in the prior quarter.
  • Over five years, Total Debt peaked at $580000.0 in Q1 2021 and troughed at $132000.0 in Q3 2025.
  • The 5-year median for Total Debt is $140000.0 (2023), against an average of $163263.2.
  • The largest YoY upside for Total Debt was 1060.0% in 2021 against a maximum downside of 76.19% in 2021.
  • A 5-year view of Total Debt shows it stood at $148000.0 in 2021, then dropped by 4.73% to $141000.0 in 2022, then decreased by 2.13% to $138000.0 in 2023, then fell by 2.9% to $134000.0 in 2024, then fell by 1.49% to $132000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Total Debt are $132000.0 (Q3 2025), $133000.0 (Q2 2025), and $134000.0 (Q1 2025).